Indivior PLC (LON:INDV – Get Free Report)’s share price was down 15.7% on Thursday . The stock traded as low as GBX 548.71 ($6.95) and last traded at GBX 732 ($9.28). Approximately 1,888,371 shares changed hands during mid-day trading, an increase of 166% from the average daily volume of 709,477 shares. The stock had previously closed at GBX 868 ($11.00).
Analysts Set New Price Targets
Separately, Jefferies Financial Group reiterated a “buy” rating and issued a GBX 1,800 ($22.81) price objective on shares of Indivior in a research note on Tuesday, December 17th.
Get Our Latest Stock Analysis on INDV
Indivior Trading Down 15.7 %
About Indivior
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
See Also
- Five stocks we like better than Indivior
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Ray Dalio’s Bridgewater Loaded Up on These Stocks in Q4 2024
- What Do S&P 500 Stocks Tell Investors About the Market?
- Walmart Faces Tariff Headwinds, Consumer Trends Remain Positive
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Tesla: 2 Reasons to Buy, 1 Reason to Run
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.